A Malbrán, M Riedl, B Ritchie, W B Smith, W Yang, A Banerji, J Hébert, G J Gleich, D Hurewitz, K W Jacobson, J A Bernstein, D A Khan, C H Kirkpatrick, D Resnick, H Li, D S Fernández Romero, W Lumry
Hereditary angioedema (HAE) is characterized by potentially life-threatening recurrent episodes of oedema. The open-label extension (OLE) phase of the For Angioedema Subcutaneous Treatment (FAST)-1 trial (NCT00097695) evaluated the efficacy and safety of repeated icatibant exposure in adults with multiple HAE attacks. Following completion of the randomized, controlled phase, patients could receive open-label icatibant (30 mg subcutaneously) for subsequent attacks. The primary end-point was time to onset of primary symptom relief, as assessed by visual analogue scale (VAS)...
August 2014: Clinical and Experimental Immunology